S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
Sell every Stock except ONE (Ad)
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
Biden and McCarthy reach a final deal to avoid US default and now must sell it to Congress
BREAKING: Tiny biotech successfully treats blindness (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
BREAKING: Tiny biotech successfully treats blindness (Ad)
'Succession' fans brace for series finale of Emmy-winning hit drama
Turkey's Erdogan wins another term as president, extends rule into 3rd decade
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
Sell every Stock except ONE (Ad)
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
Biden and McCarthy reach a final deal to avoid US default and now must sell it to Congress
BREAKING: Tiny biotech successfully treats blindness (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
BREAKING: Tiny biotech successfully treats blindness (Ad)
'Succession' fans brace for series finale of Emmy-winning hit drama
Turkey's Erdogan wins another term as president, extends rule into 3rd decade
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
Sell every Stock except ONE (Ad)
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
Biden and McCarthy reach a final deal to avoid US default and now must sell it to Congress
BREAKING: Tiny biotech successfully treats blindness (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
BREAKING: Tiny biotech successfully treats blindness (Ad)
'Succession' fans brace for series finale of Emmy-winning hit drama
Turkey's Erdogan wins another term as president, extends rule into 3rd decade
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
Sell every Stock except ONE (Ad)
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
Biden and McCarthy reach a final deal to avoid US default and now must sell it to Congress
BREAKING: Tiny biotech successfully treats blindness (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
BREAKING: Tiny biotech successfully treats blindness (Ad)
'Succession' fans brace for series finale of Emmy-winning hit drama
Turkey's Erdogan wins another term as president, extends rule into 3rd decade
NASDAQ:ONEM

1Life Healthcare (ONEM) Price Target & Analyst Ratings

Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$15.98
▼
$16.57
50-Day Range
$14.97
▼
$16.57
52-Week Range
$5.94
▼
$17.55
Volume
15.27 million shs
Average Volume
3.22 million shs
Market Capitalization
$3.37 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.18
ProfileAnalyst RatingsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

1Life Healthcare Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Hold
Based on 12 Analyst Ratings

Consensus Analyst Price Target

$17.70
7.47% Upside
High Prediction$18.00
Average Prediction$17.70
Low Prediction$15.00
TypeCurrent
5/28/22 to 5/28/23		1 Month Ago
4/28/22 to 4/28/23		3 Months Ago
2/27/22 to 2/27/23		1 Year Ago
5/28/21 to 5/28/22
Consensus Rating
Hold
Hold
Hold
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
0 Buy rating(s)
0 Buy rating(s)
0 Buy rating(s)
12 Buy rating(s)
Hold
12 Hold rating(s)
12 Hold rating(s)
13 Hold rating(s)
3 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$17.70$16.92$16.92$18.38
Predicted Upside7.47% Upside9.19% Upside9.19% Upside35.63% Upside
Get 1Life Healthcare Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for ONEM and its competitors with MarketBeat's FREE daily newsletter.


ONEM Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ONEM Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

1Life Healthcare Stock vs. The Competition

Type1Life HealthcareMedical CompaniesS&P 500
Consensus Rating Score
2.00
2.66
2.49
Consensus RatingHoldBuyHold
Predicted Upside7.47% Upside1,395.72% Upside186.83% Upside
News Sentiment RatingPositive News
Positive News
Positive News

Historical Target Prices and Ratings

Export to Excel
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
10/27/2022Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 DowngradeOutperform ➝ Neutral$18.00+5.51%
8/15/2022Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 DowngradeBuy ➝ Hold$12.00 ➝ $18.00+4.96%
8/9/2022Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Elizabeth Anderson CFA
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target$18.00+6.95%
7/27/2022Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 DowngradeBuy ➝ Hold
7/25/2022Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 DowngradeBuy ➝ Hold$18.00+4.96%
7/22/2022Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost Target$18.00+4.96%
7/22/2022SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetMarket Perform$9.00 ➝ $18.00+4.35%
7/22/2022BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 DowngradeBuy ➝ Neutral
7/22/2022Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 DowngradeBuy ➝ Neutral$14.00 ➝ $18.00+4.35%
7/22/2022Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating		George Hill
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target$12.00 ➝ $18.00+4.35%
7/21/2022Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Richard Close
Subscribe to MarketBeat All Access for the recommendation accuracy rating		DowngradeBuy ➝ Hold
7/21/2022Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 DowngradeOverweight ➝ Equal Weight$15.00 ➝ $18.00+4.90%
7/21/2022William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating		R. Daniels
Subscribe to MarketBeat All Access for the recommendation accuracy rating		DowngradeOutperform ➝ Market Perform
(Data available from 5/28/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












ONEM Price Target - Frequently Asked Questions

What is 1Life Healthcare's consensus rating and price target?

According to the issued ratings of 12 analysts in the last year, the consensus rating for 1Life Healthcare stock is Hold based on the current 12 hold ratings for ONEM. The average twelve-month price prediction for 1Life Healthcare is $17.70 with a high price target of $18.00 and a low price target of $15.00. Learn more on ONEM's analyst rating history.

Do Wall Street analysts like 1Life Healthcare more than its competitors?

Analysts like 1Life Healthcare less than other Medical companies. The consensus rating for 1Life Healthcare is Hold while the average consensus rating for medical companies is Buy. Learn more on how ONEM compares to other companies.

Does 1Life Healthcare's stock price have much upside?

According to analysts, 1Life Healthcare's stock has a predicted upside of 8.24% based on their 12-month price targets.


Stock Ratings Reports and Tools

Related Companies:
Today's Ratings:
Top Rated Stocks:
More Ratings Tools:
This page (NASDAQ:ONEM) was last updated on 5/28/2023 by MarketBeat.com Staff

My Account -